News | Cardiovascular Surgery | April 29, 2022

Paragonix Technologies SherpaPak Improves 1-Year Survival in Heart Transplant Patients in Real-World Study

GUARDIAN Registry data presented at ISHLT 2022 has shown a 72% reduction (p=0.005) in Severe PGD (primary graft dysfunction) and a 39% reduction (p=0.03) in Mechanical Circulatory Support, in addition to improvement in 1-year survival

Paragonix SherpaPak Cardiac Transport System

Paragonix SherpaPak Cardiac Transport System


April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking research from a multi-center study on one-year transplant patient outcomes following heart transplant surgery. The study compared the use of the Paragonix SherpaPak Cardiac Transport System, an FDA-cleared and CE-marked donor heart transport and preservation device, to the use of conventional cold storage using ice in the preservation of donor hearts destined for transplantation. Presented at the 2022 Annual Meeting of the International Society for Heart and Lung Transplantation on April 27, the study focused on post- transplant outcomes and survival, and utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database specifically dedicated to heart preservation.

The US Multi Center 1-year Transplant Survival Analysis of the GUARDIAN Registry included 569 adult patients who received heart transplants between October 2015 and January 2022. The analysis showed a statistically significant 72% reduction p=0.005) in Severe Primary Graft Dysfunction (PGD) rates.1,2The one-year survival rate in patients where traditional cold storage was used was 88.7%.1 In contrast, the one-year survival rate in patients where the SherpaPak was used was 96.4%. This finding represented an 8.7% increase (p=0.03) in one-year survival when using the SherpaPak for donor heart preservation.1

Additionally, several other post-operative improvements were noted by the propensity matched study in favor of the SherpaPak cohort:

  • 38.5% reduction in all post-transplant MCS (mechanical circulatory support) (p=0.03).1

  • 66.3% reduction in Post-transplant ECMO (extra corporeal membrane oxygenation) /VAD (ventricular assist device) (p=0.02)1

  • 59.7% reduction in newly placed IABP (intra-aortic balloon pump) (p=0.02)1

  • 71.9% reduction in Severe PGD (primary graft dysfunction) (p=0.005)1,2

“Our multi-center registry study was intended to assess the benefits of advanced heart preservation. We report a 1- year post transplant survival in matched cohorts from 89% in the traditional cold storage to 96% (p=0.03) in the SherpaPak cohort,” said Dr. Marzia Leacche, Richard DeVos Endowed Chair for Heart Transplant and MCS, Surgical Director, at Spectrum Health, MI, who presented the results of the study at the ISHLT 2022 Annual Meeting. “Innovations in patient care are rarely this impactful. We hypothesize that the survival benefit is due to reduction in the incidence of severe PGD (from 12% vs 3%, p=0.005)1,2 and reduced need for mechanical circulatory support after transplant.”

“The results of this study suggest that using ice to preserve and transport donor hearts is a potentially inferior method for organ preservation,” said Dr. Andreas Zuckermann, the EU Principal GUARDIAN Investigator, Director of Cardiac Transplantation, and Associate Professor of Surgery Medical University of Vienna. “A 96.4% 1-year survival rate in the propensity matched analysis utilizing the SherpaPak is an encouraging sign that this technology for advanced organ preservation is having an impact on the clinical outcomes of heart transplantation. Advanced preservation of donor hearts should be a seriously considered by all transplant centers when assessing the impact on clinical outcomes outlined in this research.”

“I look forward to contributing more to this important research as the GUARDIAN-Heart registry continues to grow, and as the trends we see within the data continue to point toward an improvement in care,” said Dr. David D’Alessandro, US Principal Investigator of the GUARDIAN study, Associate Chief of Clinical Operations in Cardiac Surgery, and Associate Professor of Surgery at Massachusetts General Hospital.

“With advanced technology like the SherpaPak, we can now demonstrate that we provide advanced care and improved outcomes for the vulnerable patient population of heart transplant recipients. With over a third of all US transplant centers utilizing the SherpaPak device, we look forward to supporting transplant centers across the US and Europe as they transition to this innovative technology as the standard of care,” said Dr. Lisa Anderson, CEO and President of Paragonix.

For more information: www.paragonix.com

Reference:

  1. Leacche et al., ISHLT Presentation 2022, Data on file
  2. Kobashigawa et al, Journal of Heart and Lung Transplantation, 2014

Related Content

News | Cardiovascular Surgery

April 21, 2023 — A Michigan Medicine study finds that Black and socioeconomically disadvantaged patients with a common ...

Home April 21, 2023
Home
News | Cardiovascular Surgery

March 24, 2023 — The American College of Surgeons (ACS), with the Society for Vascular Surgery (SVS), has launched a new ...

Home March 24, 2023
Home
News | Cardiovascular Surgery

March 15, 2023 — Researchers at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine published ...

Home March 15, 2023
Home
News | Cardiovascular Surgery

February 7, 2023 — A scientific session devoted to identifying and closing gaps in health care took place January 21 ...

Home February 07, 2023
Home
News | Cardiovascular Surgery

January 31, 2023 — Serotonin can impact the mitral valve of the heart and potentially accelerate a cardiac condition ...

Home January 31, 2023
Home
News | Cardiovascular Surgery

December 30, 2022 — Azmi Atiya, MD, an established and highly respected cardiothoracic surgeon in the San Fernando ...

Home December 30, 2022
Home
News | Cardiovascular Surgery

December 21, 2022 — The Smidt Heart Institute at Cedars-Sinai is again expanding its geographic reach and surgical ...

Home December 21, 2022
Home
News | Cardiovascular Surgery

October 24, 2022 The Smidt Heart Institute at Cedars-Sinai has selected leading vascular surgeon Donald Baril, MD, as ...

Home October 24, 2022
Home
News | Cardiovascular Surgery

October 17, 2022 — Allegheny Health Network’s (AHN) Cardiovascular Institute announced the expansion of its nationally ...

Home October 17, 2022
Home
News | Cardiovascular Surgery

September 7, 2022 — Nuwellis, Inc., a commercial-stage company focused on transforming the lives of people with fluid ...

Home September 07, 2022
Home
Subscribe Now